ABCDEFGHIJKLMNOPQRSTUVWXYZ
| Name |
Category |
| Cupid Trades & Finance Ltd. |
Fund |
| Cupid's Finance Director ditches shares post-exercise |
News |
| Cupid's marketing spend to hit profit, in talks on website sale |
News |
| Cupps Capital Is Going Big In Chi-Town |
News |
| CUQ Crosses Above 6% Yield Territory |
News |
| CUQ Dividend Yield Pushes Past 5% |
News |
| Curacao Corporation Company NV |
Company |
| Curacao International Trust Co., N.v. |
Bank |
| Curanice Consulting N.V. |
Company |
| Curanum AG |
Fund |
| curasan AG |
Fund |
| Curaxis Pharmaceutical Corp |
Fund |
| CURAXIS PHARMACEUTICAL CORP Files SEC form 10-Q, Quarterly Report |
News |
| CURAXIS PHARMACEUTICAL CORP Files SEC form 8-K, Bankruptcy or Receivership, Triggering Events That Accelerate or Incr |
News |
| CURAXIS PHARMACEUTICAL CORP Financials |
News |
| Curing Parkinson's: The Alternative Approach - Is There Money To Be Made? |
News |
| Curis Announces Appointment of Mani Mohindru, Ph.D., as Vice President of Corporate Strategy and Investor Relations |
News |
| Curis Announces Approval of Erivedge(R) in Australia |
News |
| Curis Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at ASCO 2013 Annual Meeting |
News |
| Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting |
News |
| Curis Earnings: Here’s Why Investors Don’t Like These Results |
News |
| CURIS INC Files SEC form 10-Q, Quarterly Report |
News |
| CURIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security |
News |
| CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Officer |
News |
| CURIS INC Financials |
News |
Page 1043 of 1069
Page 1043 of 1069